{"url_path":"/sec/armp/8-k/2026-06-23/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-076627-index.html","accession_number":"0001104659-26-076627","cik":"0000921114","ticker":"ARMP","issuer_name":"Armata Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-076627-index.html","primary_entity_key":"0000921114","primary_entity_name":"Armata Pharmaceuticals, Inc."},"word_count":81,"has_tables":true,"body_markdown":"**Item 8.01**\n**Other Events.**\n\n \n\nOn June 23, 2026, the Company issued a press release announcing that\nit had received $2.5 million of additional non-dilutive award funding from the U.S. Department of Defense for the development of AP-SA02,\nthe Company's intravenously administered *Staphylococcus aureus* phage product candidate, to treat complicated bacteremia infections.\nThe full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form\n8-K and incorporated herein by reference."}